{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:03:31Z","timestamp":1779753811588,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Guizhou Qiannan Infectious Disease Control Talent Base Project","award":["NO.RCJD2020-67"],"award-info":[{"award-number":["NO.RCJD2020-67"]}]},{"name":"The Guangzhou Science and Technology Plan Project","award":["NO. 202103000060"],"award-info":[{"award-number":["NO. 202103000060"]}]},{"name":"The Qiannan Liver Disease Clinical Medical Research Center Project","award":["NO. Qiannan ke he zi\uff082020\uff0905"],"award-info":[{"award-number":["NO. Qiannan ke he zi\uff082020\uff0905"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-45509-x","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T05:38:10Z","timestamp":1775281090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The aMAP score combined with plasma cfDNA methylation testing for risk stratification in hepatitis population: a case-control study"],"prefix":"10.1038","volume":"16","author":[{"given":"Dianyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhong","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingyao","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"key":"45509_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel, A., Meyer, T., Sapisochin, G., Salem, R. & Saborowski, A. Hepatocellular carcinoma. Lancet 400, 1345\u20131362 (2022).","journal-title":"Lancet"},{"key":"45509_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74, 229\u2013263 (2024).","journal-title":"CA Cancer J Clin"},{"key":"45509_CR3","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 4, 47\u201353 (2024).","journal-title":"J Natl Cancer Cent"},{"key":"45509_CR4","first-page":"203","volume":"4","author":"H Zeng","year":"2024","unstructured":"Zeng, H. et al. Cancer survival statistics in China 2019\u20132021: A multicenter, population-based study. J Natl Cancer Cent 4, 203\u2013213 (2024).","journal-title":"J Natl Cancer Cent"},{"key":"45509_CR5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani, C. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37\u2008513\u2008025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023\u20131075 (2018).","journal-title":"Lancet"},{"key":"45509_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.106298","volume":"89","author":"B Wen","year":"2024","unstructured":"Wen, B. et al. Relative contribution of hepatitis B and C viruses in primary liver cancer in China: A systematic review and meta-analysis. J Infect 89, 106298 (2024).","journal-title":"J Infect"},{"key":"45509_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2023-100036","volume":"2","author":"B Chang","year":"2024","unstructured":"Chang, B. et al. Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: A retrospective study of 136 571 patients with chronic liver diseases. eGastroenterology 2, e100036 (2024).","journal-title":"eGastroenterology"},{"key":"45509_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1510563","volume":"12","author":"S Li","year":"2025","unstructured":"Li, S. et al. Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels. Front Nutr 12, 1510563 (2025).","journal-title":"Front Nutr"},{"key":"45509_CR9","first-page":"599","volume":"13","author":"Y Deng","year":"2025","unstructured":"Deng, Y., Meng, T., You, H., Jia, J. & Wang, Y. Epidemiology, achievements, and challenges in the elimination of Hepatitis B in China. J Clin Transl Hepatol 13, 599\u2013604 (2025).","journal-title":"J Clin Transl Hepatol"},{"key":"45509_CR10","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"45509_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","volume":"11","author":"M Omata","year":"2017","unstructured":"Omata, M. et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int. 11, 317\u2013370 (2017).","journal-title":"Hepatol. Int."},{"key":"45509_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jhep.2020.07.025","volume":"73","author":"R Fan","year":"2020","unstructured":"Fan, R. et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. J. Hepatol. 73, 1368\u20131378 (2020).","journal-title":"J. Hepatol."},{"key":"45509_CR13","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1038\/s41467-023-39055-7","volume":"14","author":"D Cheishvili","year":"2023","unstructured":"Cheishvili, D. et al. A high-throughput test enables specific detection of hepatocellular carcinoma. Nat. Commun. 14, 3306 (2023).","journal-title":"Nat. Commun."},{"key":"45509_CR14","doi-asserted-by":"publisher","first-page":"e1652","DOI":"10.1002\/ctm2.1652","volume":"14","author":"DZ Guo","year":"2024","unstructured":"Guo, D. Z. et al. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study. Clin. Transl Med. 14, e1652 (2024).","journal-title":"Clin. Transl Med."},{"key":"45509_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13148-025-01920-1","volume":"17","author":"Z Xu","year":"2025","unstructured":"Xu, Z. et al. Clinical performance evaluation of a plasma dual-target methylation test for the detection of primary liver cancer: a multicenter study. Clin. Epigenetics. 17, 121 (2025).","journal-title":"Clin. Epigenetics"},{"key":"45509_CR16","doi-asserted-by":"publisher","first-page":"2299044","DOI":"10.1080\/15592294.2023.2299044","volume":"19","author":"Y Zhao","year":"2024","unstructured":"Zhao, Y. et al. Plasma methylated GNB4 and Riplet as a novel dual-marker panel for the detection of hepatocellular carcinoma. Epigenetics 19, 2299044 (2024).","journal-title":"Epigenetics"},{"key":"45509_CR17","first-page":"e70017","volume":"7","author":"Q Yang","year":"2024","unstructured":"Yang, Q. et al. Analytical and Diagnostic Performance of a Dual-Target Blood Detection Test for Hepatocellular Carcinoma. Cancer Rep. (Hoboken). 7, e70017 (2024).","journal-title":"Cancer Rep. (Hoboken)"},{"key":"45509_CR18","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","volume":"12","author":"H-I Yang","year":"2011","unstructured":"Yang, H.-I. et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): Development and validation of a predictive score. Lancet Oncol. 12, 568\u2013574 (2011).","journal-title":"Lancet Oncol."},{"key":"45509_CR19","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2019.12.005","volume":"72","author":"T-F Yip","year":"2020","unstructured":"Yip, T.-F. et al. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol 72, 847\u2013854 (2020).","journal-title":"J Hepatol"},{"issue":"17","key":"45509_CR20","doi-asserted-by":"publisher","first-page":"32248","DOI":"10.1016\/j.jhep.2017.07.033","volume":"S0168-8278","author":"SA Sharma","year":"2017","unstructured":"Sharma, S. A. et al. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. J. Hepatol. S0168-8278 (17), 32248\u201332241. https:\/\/doi.org\/10.1016\/j.jhep.2017.07.033 (2017).","journal-title":"J. Hepatol."},{"key":"45509_CR21","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1002\/hep.30244","volume":"69","author":"JB Kisiel","year":"2019","unstructured":"Kisiel, J. B. et al. Hepatocellular carcinoma detection by plasma methylated DNA: Discovery, Phase I pilot, and Phase II clinical validation. Hepatology 69, 1180\u20131192 (2019).","journal-title":"Hepatology"},{"key":"45509_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1065693","volume":"13","author":"W Liang","year":"2022","unstructured":"Liang, W. et al. Circulating tumour cell combined with DNA methylation for early detection of hepatocellular carcinoma. Front Genet 13, 1065693 (2022).","journal-title":"Front Genet"},{"key":"45509_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332034","author":"H El-Serag","year":"2024","unstructured":"El-Serag, H. et al. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis. Gut https:\/\/doi.org\/10.1136\/gutjnl-2024-332034 (2024).","journal-title":"Gut"},{"key":"45509_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102381","volume":"15","author":"A Elgenidy","year":"2025","unstructured":"Elgenidy, A. et al. Assessing the predictive accuracy of the aMAP risk score for hepatocellular carcinoma (HCC): Diagnostic test accuracy and meta-analysis. J Clin Exp Hepatol 15, 102381 (2025).","journal-title":"J Clin Exp Hepatol"},{"key":"45509_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/JHC.S308587","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Using the aMAP risk score to predict late recurrence following radiofrequency ablation for hepatocellular carcinoma in Chinese population: A multicenter study. J Hepatocell Carcinoma 8, 837\u2013850 (2021).","journal-title":"J Hepatocell Carcinoma"},{"key":"45509_CR26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1159\/000530987","volume":"101","author":"H Ohama","year":"2023","unstructured":"Ohama, H. et al. Usefulness of aMAP risk score for predicting recurrence after curative treatment for hepatocellular carcinoma within Milan Criteria. Oncology 101, 575\u2013583 (2023).","journal-title":"Oncology"},{"key":"45509_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/IJGM.S343457","volume":"15","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. aMAP score as a predictor for long-term outcomes in patients with HBV-related acute-on-chronic liver failure. Int. J. Gen. Med. 15, 407\u2013415 (2022).","journal-title":"Int. J. Gen. Med."},{"key":"45509_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/jvh.13884","volume":"30","author":"H He","year":"2023","unstructured":"He, H. et al. Risk-stratified approach by aMAP score for community population infected with hepatitis B and C to guide subsequent liver cancer screening practice: A cohort study with 10-year follow-up. J. Viral Hepat. 30, 859\u2013869 (2023).","journal-title":"J. Viral Hepat."},{"key":"45509_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/hepr.13678","volume":"51","author":"H Yoshiji","year":"2021","unstructured":"Yoshiji, H. et al. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol. Res. 51, 725\u2013749 (2021).","journal-title":"Hepatol. Res."},{"key":"45509_CR30","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45509-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45509-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45509-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T23:27:07Z","timestamp":1779751627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-45509-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["45509"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-45509-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Institutional Review Board of the The People\u2019s Hospital of Qiannan granted ethical approval to the study with the following ethical approval number: 2024-qnzy-20.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"16214"}}